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Serum calcitriol concentrations measured with a new direct automated assay in a large 
population of adult healthy subjects and in various clinical situations. 
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Abstract 
The measurement of calcitriol [1,25(OH2)D], is important for the differential diagnosis of 
several disorders of calcium/phosphorus metabolism but is time-consuming and tricky. We 
measured serum calcitriol with a new automated direct assay on the Liaison XL platform in 
888 healthy French Caucasian subjects aged 18-89 years, 32 patients with a surgically-proven 
PHPT, 32 pregnant women at the end of the first and at the end of the third trimester, and 24 
Dialysis patients before and after one year of supplementation with vitamin D3 or placebo. 
The mean calcitriol concentration (±SD) in the healthy population was 52.9±14.5 ng/L with a 
95 % CI interval of 29-83.6 ng/L.  In PHPT patients, calcitriol concentration was 81.6±29.0 
ng/L, 15 of them (46.9%) having a concentration >83.6 ng/L. In pregnant women, calcitriol 
was 80.4±26.4 ng/L at the end of the first trimester, and 113.1±33.0 ng/L at the end of the 
third trimester, 12 (37.5%) and 26 (81.3%) of them having a calcitriol >83.6 ng/L at first and 
third trimester respectively. In 14 dialysis patients, calcitriol was 9.5 ± 7.7 ng/L and rose to 
19.3 ng/L after one year of supplementation with 50,000 IU vitamin D3/month. In 10 other 
dialysis patients, calcitriol was 9.9±2.9 ng/L and remained stable (12.4±3.7 ng/L) after one 
year of placebo. In conclusion, this new automated calcitriol assay, in addition to presenting 
excellent analytical performances, gives the expected variations in patients compared to 
“normal” values obtained in an extensive reference population. 
 
Key words: calcitriol; vitamin D; reference values; primary hyperparathyroidism; dialysis ; 
pregnancy 
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Hoghlights  
- A new, more sensitive, assays for 1.25(OH)2 vitamin D is now available on the market 
- This assay allows performing new basic and clinical studies 
- Reference ranges for 1.25(OH)2D have been established on a 888 healthy individuals cohort 
- Well characterized clinical populations have been studied and compared with these results 
- 25OHD concentration is the most closely correlated to 1,25(OH)2D serum concentration in 
healthy subjects, both in univariate and multivariate analysis 
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1.Introduction 
The active vitamin D metabolite, 1,25 dihydroxyvitamin D  [1,25(OH2)D], also called 
calcitriol, is secreted into the bloodstream by the cells of the renal proximal tubule and binds 
to the vitamin D receptor (VDR) in several distant tissues to exert genomic effects. It must 
thus be considered as a real hormone [1]. Renal 1a-hydroxylation of 25-hydroxyvitamin D 
(25OHD), the precursor of calcitriol produced by the liver, is tightly regulated, mainly 
stimulated by parathyroid hormone (PTH) and inhibited by Fibroblast Growth Factor 23 
(FGF23). Calcitriol is also produced by numerous tissues where it acts in an intracrine manner 
[2]. The measurement of calcitriol in serum must not be used to evaluate the vitamin D status 
which is consensually assessed through the measurement of 25OHD [3]. However, it is 
important for the differential diagnosis of several disorders of calcium/phosphorus 
metabolism, especially in case of hypercalcemia, hypercalciuria, and low PTH level [4], or in 
case of rickets/osteomalacia which persists after vitamin D supplementation [5]. Calcitriol 
serum levels are modified in many clinical situations, increased for example during pregnancy 
[6], or primary hyperparathyroidism (PHPT) [7], and decreased in chronic kidney disease 
(CKD) [8] or hypoparathyroidism [9]. 
The measurement of 1,25(OH)2D concentration in serum is not an easy task due to its 
hydrophobic nature and because it circulates at picomolar levels compared to 25OHD, which 
has one less hydroxyl residue and circulates at a 1000-fold higher concentration. Currently 
available 1,25(OH)2D assays are either immunoassays [10; 11] or HPLC/LC-MSMS methods 
[12; 13] that require quite a large amount of serum (most often 0.5 mL) and a complicated and 
time-consuming extraction step to eliminate potentially interfering compounds. Very recently, 
a new automated rapid (65 minutes to obtain the first result), and with a high throughput (90 
tests/hour) 1,25(OH)2D assay that does not require an extraction step became available on the 
LIAISON XL automated platform [14]. Another potential advantage of this new assay is that 
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it requires a much smaller sample volume (75 µL+ adjustable dead volume of  50 µL at least) 
than the other 1,25(OH)2D assays, a point that may be especially interesting in paediatric 
settings.  A recently published evaluation of this new kit reported excellent analytical 
performances [14].  
The aim of the present study was to use a large, well-defined cohort of French healthy 
subjects to establish serum 1,25(OH)2D reference values with this new assay. We also 
measured 1,25(OH)2D in several well-characterized groups of patients. 
2.Subjects and methods 
2.1.Healthy subjects and patients 
We enrolled healthy volunteers who participated in the VARIETE study, a population-based 
cross-sectional study designed to recruit a reference population in order to harmonize normal 
serum IGF-I values in adults (ClinicalTrials.gov identifier: NCT01831648). They were 
recruited between January 2011 and February 2012 by the clinical research units of 10 
university hospitals distributed throughout France. To be included in the study, subjects had to 
have a normal physical work-up (weight, height, blood pressure, nutritional status and 
gonadal/sexual status), normal laboratory values determined after an overnight fast (plasma 
sodium, potassium, calcium, phosphate, creatinine, glycemia, total cholesterol, liver enzymes, 
TSH, blood cell counts, albuminemia, prothrombin time, and HIV and HCV serology), age 
18-89 years and BMI between 19 and 28 kg/m², and to give their written informed consent to 
participate in the study. The exclusion criteria were a medical history of thyroid, renal, 
hepatic, cardiovascular, pulmonary, intestinal or psychiatric disorders, cancer, epilepsy, 
intercurrent illness occurring during the week preceding inclusion, current consumption of 
tobacco or other toxics, and treatment potentially modifying IGF-I or calcium/phosphorus 
metabolism (antiandrogens or antiestrogens, loop diuretics, hydrochlorothiazide, CYP-
inducing drugs). In addition to the blood samples necessary for the screening biological 
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evaluation, 50 mL of whole blood and 30 mL of EDTA blood was obtained from each 
subject. Blood was promptly centrifuged (3000 g at 4°C), and serum or plasma was aliquoted 
in polypropylene tubes that were immediately stored at -80°C. This study was funded by 
Programme Hospitalier de Recherche Clinique, French Ministry of Health, N° P081216 / 
IDRCB 2009-A00892-55, and was approved by the Paris-Sud Ethics Committee in November 
2009. 
We also studied serum samples from 32 patients with PHPT before parathyroid surgery. In 
these patients, the diagnosis of PHPT was ascertained by a calcium load test showing an 
insufficient fall in serum PTH when ionized calcemia rose well above the upper normal limit. 
In those with either normal total calcemia or normal ionized calcemia (n=13), an IV calcium 
load test was performed as described in [15]. These patients were osteoporotic (low bone 
mineral density [BMD] and/or low-trauma fracture) and were initially referred to our tertiary 
care center for etiological diagnosis of abnormal calcium/phosphorus or related hormone 
levels detected during a screening biological evaluation aimed at ruling out secondary causes 
of osteoporosis. We requested that the physician who referred the patient prescribe vitamin D 
if the 25OHD concentration was low, before investigations in our unit. All patients in this 
group underwent successful parathyroidectomy, as confirmed by pathological examination of 
parathyroid tissue removed during surgery.  
We also obtained serum samples of 32 pregnant women participating in the FEPED study, an 
ongoing prospective observational study of the association between serum 25OHD levels and 
the risk of preeclampsia (ClinicalTrials.gov identifier: NCT01648842). In these 32 women, 
blood was drawn at the end of the first trimester and at the end of the third trimester of 
pregnancy. They received a 100,000 IU vitamin D3 dose at the beginning of the third 
trimester of pregnancy as it is the rule in France for the prevention of neonatal hypocalcemia. 
The FEPED study was funded by Programme Hospitalier de Recherche Clinique, French 
A
C
C
E
P
T
E
D
 M
A
N
U
S
C
R
IP
T
ACCEPTED MANUSCRIPT
 8 
Ministry of Health, N° NI10024-ID RCB 2011-A00355-36 and was approved by the CPP Ile 
de France IV Ethics Committee in April 2011.  
Finally, we included sera from 24 haemodialysis patients who participated in a pilot 
randomized study of vitamin D supplementation, registered with a Belgian clinical trial 
number (B70720084117) [16]. In these patients, blood was drawn before and after one year of 
vitamin D supplementation (50,000IU vitamin D3 per month ; n=14) or placebo (n=10) just 
before a dialysis session. 
2.2.Laboratory methods 
The biological parameters of the healthy volunteer screening evaluation were determined 
locally by the laboratories attached to the clinical research units, using standard chemistry. 
The CKDepi formula was used to estimate glomerular filtration rate (eGFR). PTH, 25OHD, 
and 1,25(OH)2D measurements were centralized and done in batches by means of 
immunochemiluminescent assays on the LIAISON XL automated platform (DiaSorin, 
Stillwater, Mn, USA), using serum samples that had never been thawed. The new 1,25(OH)2D 
assay is a sandwich assay that uses the ligand binding domain (LBD) of the VDR as a 
1,25(OH)2D capture molecule. Reaction conditions were chosen at which 1,25(OH)2D binds 
the VDR with an approximately 200-fold higher affinity than 25OHD, while the vitamin D 
binding protein binds 1,25(OH)2D  with a 10 to 100-fold lower affinity than 25OHD, leaving 
thus a 2,000-20,000 fold differential favouring the transfer of 1,25(OH)2D from the VDBP 
with binding to the recombinant VDR-LBD. The assay then exploits the conformational 
change of the LBD induced by 1,25(OH)2D binding with the use of paramagnetic 
microparticles coated with a specific monoclonal antibody which recognizes this induced 
1,25(OH)2D-bound LBD conformation. After a washing step aimed at eliminating unbound 
LBD, a second isoluminol-labelled anti-LBD antibody is added and binds to the 1,25(OH)2D-
LBD complex already bound to the solid-phase. After eliminating the excess (unbound) 
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second antibody, luminescence is counted and is proportional to the 1,25(OH)2D  present in 
the serum sample. Analytical performances of the new 1,25(OH2)D assay have been reported 
in [14]. 
2.3.Statistical analysis 
Quantitative variables are reported as means ± SD. The median, quartile (Q) 1 (25
th
 
percentile), Q3 (75
th
 percentile), and interquartile range (IQR) of 1,25(OH)2D values are 
reported for the healthy subjects. We used the Horn algorithm to determine the 1,25(OH)2D 
reference range [17]. We first detected outliers, defined as 1,25(OH)2D concentrations below 
Q1-1.5 IQR and above Q3+1.5 IQR after log transformation of the raw values. We then 
calculated the 95% confidence interval in the remaining subjects after eliminating the outliers. 
Paired data were compared with the Wilcoxon test. Unpaired data were compared with the 
Mann-Whitey U-test. A p value <0.05 was considered significant. 
3.Results 
3.1.Healthy subjects  
Nine hundred seventy-two Caucasian subjects were initially recruited. Two were excluded 
because their informed consent was not available, and another 60 were excluded because of 
abnormal values in the screening evaluation. Among the remaining 910 subjects, no serum 
sample was available for 1,25(OH)2D testing in 22 cases. The study population thus consisted 
of 888 subjects, whose main characteristics are summarized in Table 1. The mean 
1,25(OH)2D value in these 888 subjects was 52.9 ± 14.5 ng/L (median: 51.6 ng/L; Q1: 42.6 
ng/L; Q3: 61.8 ng/L; IQR: 19.2 ng/L). After exclusion of twelve outliers (two high values, ten 
low values), the range of 1,25(OH)2D concentrations (2.5
th
-97.5
th
 percentile) was 29.0-83.6 
ng/L. Mean 1,25(OH)2D level was slightly higher in women than in men (54.0 ± 15.1 ng/L 
and 51.8 ± 13.9 ng/L respectively; p=0.026) but without any difference in the upper and lower 
limit of normal. .  
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3.2.Patients  
The main characteristics of the 32 PHPT patients are presented in table 2. Their mean 
1,25(OH)2D  concentration (81.6 ± 29.0 ng/L) was significantly higher than in the healthy 
population (p<0.001). Fifteen of them (46.9%) had a 1,25(OH)2D  concentration above our 
upper limit of normal of 83.6 ng/L.  
In the 32 pregnant women, the mean 1,25(OH)2D  concentration at the end of the first 
trimester (80.4 ± 26.4 ng/L) was significantly higher than in the healthy population (p<0.001), 
and significantly increased to 113.1 ± 33.0 ng/L at the end of the third trimester (p<0.001) as 
did their 25OHD serum concentration which increased significantly from 18.5 ± 9.9 ng/mL to 
39.8 ± 11.8 ng/mL. Twelve (37.5%), and 26 (81.3 %) of them had a 1,25(OH)2D  
concentration above 83.6 ng/L at the end of the first and third trimester respectively. Calcitriol 
concentrations of these 3 groups of patients are summarized in figure 1.  
Eight of the 24 dialysis patients (5 in the vitamin D group, and 3 in the placebo group) had a 
1,25(OH)2D concentration below the LOQ of 5 ng/L before vitamin D supplementation, while 
2 patients in the placebo group and none in the vitamin D group had such a value after one 
year of supplementation. They were attributed an arbitrary 1,25(OH)2D concentration of 4 
ng/L. In the 14 HD patients who received vitamin D, serum 25OHD increased from 11.9 ± 4.9 
ng/mL to 36.9 ± 9.3 ng/mL (p=0.001), and serum 1,25(OH)2D  increased from 9.5 ± 7.7 ng/L 
to 19.3 ± 9.7 ng/L (p=0.001) after one year of supplementation. Three of them (21.4 %) 
reached a normal 1,25(OH)2D concentration (>29 ng/L) at one year (Figure 2). By contrast 
25OHD (9.9 ± 2.9 ng/mL before, and 12.4 ± 3.7 ng/mL after supplementation) and 
1,25(OH)2D  (7.4 ± 3.9 before, and 10.7 ± 7.1 ng/L after supplementation) concentration did 
not change in the placebo group, and none of the subjects from this group had a normal 
1,25(OH)2D  level at any time-point.  
4.Discussion 
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In the present study, we measured serum 1,25(OH)2D concentration with a new automated, 
direct immunoassay in a large cohort of healthy French adult subjects. Using a recommended 
statistical method  [17], we propose an adult reference range of 29-83.6 ng/L for serum 
1,25(OH)2D concentration with this new assay. In several well-characterized groups of 
patients, we found the expected percentages of either high (PHPT patients and pregnant 
women) or low (dialysis patients) calcitriol concentrations.  
Indeed calcitriol concentration was elevated (i.e. >83.6 ng/L) in approximately one of two 
PHPT patients, a finding consistent with previous studies [7; 18-23]. In these patients, 
increased 1,25(OH)2D levels are believed to be due to increased PTH secretion which is the 
main stimulator of renal 1a-hydroxylase [8 ; 22]. Clinical associations of increased 
1,25(OH)2D concentration in PHPT differed among studies. In one study, elevated 
1,25(OH)2D was present in PHPT patients with renal stone disease but not in those with low 
bone mass [7]. In contrary, elevated 1,25(OH)2D level was associated with increased bone 
turnover and low BMD in PHPT patients before surgery [21; 24], and weakly but significantly 
with the change in spine BMD one year after parathyroid surgery [25]. 
Similarly, two of five and four of five pregnant women had a 1,25(OH)2D serum 
concentration >83.6 ng/L at the end of the first and the third trimester of pregnancy 
respectively. Here again, this is in accordance with previously published studies [10; 26-28]. 
This increase in 1,25(OH)2D throughout pregnancy seems largely independent of PTH which 
has been found to be decreased during pregnancy in some studies [28], seems to be of both 
renal and placental origin [29], and is probably related to various factors such as an increase 
in the circulating level of vitamin D-binding protein (VDBP), and stimulation by prolactin, 
IGF-I, and PTHrP. One extremely remarkable point is that pregnant women remain 
normocalcemic despite having 1,25(OH)2D concentrations that are able to induce a frank 
hypercalcemia in some clinical conditions such as sarcoidosis [4]. 
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Calcitriol concentration was low, but often detectable, in our CKD patients treated by chronic 
haemodialysis, and significantly increased after vitamin D supplementation. An increase in 
serum 1,25(OH)2D after supplementation with 25OHD [30; 31] or vitamin D3 [32] in dialysis 
patients has previously been reported, and is clearly of extra-renal origin as evidenced by 
studies that shown an increase in  1,25(OH)2D serum level during vitamin D supplementation 
in anephric patients [33; 34]. To our knowledge, it remains to be shown whether the well-
known decrease in PTH concentration during vitamin D or 25OHD supplementation in 
dialysis patients [16; 32; 35] is tightly correlated with the increase in 1,25(OH)2D 
concentration.  
In conclusion, this new 1,25(OH)2D assay, in addition to presenting excellent analytical 
performances, detects the expected variations in selected groups of patients. As it requires 
much less sample than the other currently available assays and is extremely rapid and easy to 
use, it should become the method of choice for measuring serum 1,25(OH)2D in routine 
practice. It should be also of great interest in clinical research, specially for measuring 
1,25(OH)2D in large cohorts of healthy or diseased persons. 
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Table 1. Characteristics of the healthy subjects participating in the VARIETE study. 
 Mean +/-SD (range) 
Gender:  men/women 466/432 
Age (years) 39.7 ± 18.6 (18- 89) 
BMI (kg/m²) 23.0 ± 2.4 (18.5-28) 
Serum 25OHD (ng/mL) 23.8 ± 8.1 (5.2-59.4) 
Serum PTH (ng/L) 20.6 ± 8.0 (7.4-79.0) 
Serum calcium (mmol/L) 2.30 ± 0.10 (2.10-2.60) 
Serum phosphate (mmol/L) 1.09 ± 0.18 (0.75-1.51) 
Serum albumin (g/L) 43.0 ± 3.9 (32.6-50) 
eGFR (CKDepi) (mL/min/1.73 m²) 100 ± 7 (60-144) 
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 Table 2 : Main characteristics of the 32 patients with surgically-proven PHPT before 
parathyroidectomy. 
Gender : men/women 2/30 
Age (years) 66.6 ± 10.9 (min : 43-max: 89) 
Serum total calcium (mmol/L) 2.63 ± 0.14 
Serum ionized calcium (mmol/L) 1.37 ± 0.07 
Serum 25OHD (ng/mL) 32.0 ± 9.5 
Serum 3
rd
-generation PTH (ng/L) 48.9 ± 23.3 
Serum 1,25OH2D (ng/L) 81.0 ± 29.0  
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 Figure 1 : Calcitriol concentration in patients with primary hyperparathyroidism (PHPT), 
pregnant women at the end of the first trimester, and at the end of the third trimester of 
pregnancy. The mean calcitriol concentration of these 3 groups is significantly higher than the 
mean level in the normal population. The two horizontal lines are the lower (29 ng/L) and 
upper (83.6 ng/L) normal limit that we have determined in the VARIETE population.  
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Figure 2 : Evolution of serum calcitriol concentration over a one year period of 
supplementation with vitamin D3, 50,000 IU/month (A) or placebo (B). The solid horizontal 
lines are the lower limit of normal (29 ng/L) as determined in the VARIETE population. 
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Highlights  
- A new, more sensitive, assays for 1.25(OH)2 vitamin D is now available on the market 
- This assay allows performing new basic and clinical studies 
- Reference ranges for 1.25(OH)2D have been established on a 888 healthy individuals cohort 
- Well characterized clinical populations have been studied and compared with these results 
- 25OHD concentration is the most closely correlated to 1,25(OH)2D serum concentration in 
healthy subjects, both in univariate and multivariate analysis 
